Nanotoxicity: the growing need for in vivo study

Current Opinion in Biotechnology

Volumn 18, Issue 6, 2007, Pages 565-571

  Fischer, Hans C ^a,b   Chan, Warren CW ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL SYSTEMS; CELL CULTURE; METABOLISM; NANOSTRUCTURES; PROTEINS; SURFACE CHEMISTRY;

NANOTOXICITY; UNIQUE BIODISTRIBUTION;

TOXICITY;

NANOMATERIAL;

IN VITRO STUDY; IN VIVO STUDY; NANOCHEMISTRY; NANOTECHNOLOGY; NANOTOXICOLOGY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING;

ANIMALS; NANOPARTICLES; NANOSTRUCTURES; NANOTECHNOLOGY; TOXICITY TESTS;

ANIMALIA;

EID: 37549042771     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2007.11.008     Document Type: Review

References (54)

1. Medintz I.L., Uyeda H.T., Goldman E.R., and Mattoussi H. Quantum dot bioconjugates for imaging, labeling and sensing. Nat Mater 4 (2005) 435-446
2. Caruthers S.D., Wickline S.A., and Lanza G.M. Nanotechnological applications in medicine. Curr Opin Biotech 18 (2007) 26-30
3. In: Kumar C. (Ed). Nanomaterials for Medical Diagnosis and Therapy (2007), Wiley-VCH, Weinheim
4. Akerman M.E., Chan W.C., Laakkonen P., Bhatia S.N., and Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci 99 (2002) 12617-12621
5. Gao X., Cui Y., Levenson R.M., Chung L.W.K., and Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 22 (2004) 969-976
6. Nanoscience and nanotechnologies: opportunities and uncertainties. Edited by The Royal Society, Royal Academy of Engineering; 2004.
7. Maynard A.D., Aitken R.J., Butz T., Colvin V., Donaldson K., Oberdorster G., Philbert M.A., Ryan J., Seaton A., Stone V., et al. Safe handling of nanotechnology. Nature 444 (2006) 267-269
8. Tsuji J.S., Maynard A.D., Howard P.C., James J.T., Lam C-w, Warheit D.B., and Santamaria A.B. Research strategies for safety evaluation of nanomaterials, Part IV: Risk assessment of nanoparticles. Toxicol Sci 89 (2006) 42-50
9. Characterising the potential risks posed by engineered nanoparticles: a first UK government research report. Edited by Department for Environment FaRA; 2005.
10. Colvin V.L. The potential environmental impact of engineered nanomaterials. Nat Biotechnol 21 (2003) 1166-1170
11. Oberdorster G., Oberdorster E., and Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 113 (2005) 823-839
12. Oberdorster G., Stone V., and Donaldson K. Toxicology of nanoparticles: a historical perspective. Nanotoxicology 1 (2007) 2-25. Thorough review of the temporal development of the field of nanoparticulate-bio interaction, with a treatment of fullerene toxicology and environmental concerns.
13. Dobrovolskaia M.A., and McNeil S.E. Immunological properties of engineered nanomaterials. Nat Nano 2 (2007) 469-478. Excellent review of current state of nano-immunotoxicity research, clearly laying out unknowns within the areas of blood contact, immunostimulation and suppression.
14. Duncan R., and Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 57 (2005) 2215-2237
15. Klostranec J.M., and Chan W.C.W. Quantum dots in biological and biomedical research: recent progress and present challenges. Adv Mater 18 (2006) 1953-1964
16. Nel A., Xia T., Maedler L., and Li N. Toxic potential of materials at the nanolevel. Science 311 (2006) 622-627
17. Smart S.K., Cassady A.I., Lu G.Q., and Martin D.J. The biocompatibility of carbon nanotubes. Carbon 44 (2006) 1034-1047. Worthwhile review of all aspects of current state of knowledge.
18. Borm P., Klaessig F.C., Landry T.D., Moudgil B., Pauluhn J., Thomas K., Trottier R., and Wood S. Research strategies for safety evaluation of nanomaterials, part V: role of dissolution in biological fate and effects of nanoscale particles. Toxicol Sci 90 (2006) 23-32
19. Xia T., Kovochich M., Brant J., Hotze M., Sempf J., Oberley T., Sioutas C., Yeh J.I., Wiesner M.R., and Nel A.E. Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett 6 (2006) 1794-1807
20. Chithrani B.D., Ghazani A.A., and Chan W.C.W. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 6 (2006) 662-668
21. Chen F., and Gerion D. Fluorescent CdSe/ZnS nanocrystal-peptide conjugates for long-term, nontoxic imaging and nuclear targeting in living cells. Nano Lett 4 (2004) 1827-1832
22. Deng X., Jia G., Wang H., Sun H., Wang X., Yang S., Wang T., and Liu Y. Translocation and fate of multi-walled carbon nanotubes in vivo. Carbon 45 (2007) 1419-1424
23. Derfus A.M., Chan W.C.W., and Bhatia S.N. Probing the cytotoxicity of semiconductor quantum dots. Nano Lett 4 (2004) 11-18
24. Powers K.W., Brown S.C., Krishna V.B., Wasdo S.C., Moudgil B.M., and Roberts S.M. Research strategies for safety evaluation of nanomaterials, Part VI: Characterization of nanoscale particles for toxicological evaluation. Toxicol Sci 90 (2006) 296-303
25. Ryman-Rasmussen J.P., Riviere J.E., and Monteiro-Riviere N.A. Variables influencing interactions of untargeted quantum dot nanoparticles with skin cells and identification of biochemical modulators. Nano Lett 7 (2007) 1344-1348
26. Lee H.A., Imran M., Monteiro-Riviere N.A., Colvin V.L., Yu W.W., and Riviere J.E. Biodistribution of quantum dot nanoparticles in perfused skin: evidence of coating dependency and periodicity in arterial extraction. Nano Lett 7 (2007) 2865-2870. A tissue interaction studies with nanoparticles in live skin, fit to a multicompartment model, showing a phenomenon of skin-QD interaction not observable in vitro.
27. Yang R.S.H., Chang L.W., Wu J.-P., Tsai M.-H., Wang H.-J., Kuo Y.-C., Yeh T.-K., Yang C.S., and Lin P. Persistent tissue kinetics and redistribution of nanoparticles, quantum dot 705, in mice: ICP-MS quantitative assessment. Environ Health Perspect 115 (2007) 1339-1343
28. Lundqvist M., Sethson I., and Jonsson B.H. Protein adsorption onto silica nanoparticles: conformational changes depend on the particles' curvature and the protein stability. Langmuir 20 (2004) 10639-10647. A detailed, insightful study using circular dichroism and NMR to demonstrate the effect of surface curvature on conformational changes in Human carbonic anhydrase I.
29. Cedervall T., Lynch I., Lindman S., Berggard T., Thulin E., Nilsson H., Dawson K., and Linse S. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci 104 (2007) 2050-2055
30. Cedervall T., Lynch I., Foy M., Berggard T., Donnelly S.C., Cagney G., Linse S., and Dawson K.A. Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angewandte Chemie - Int Ed 46 (2007) 5754-5756. A clear presentation of compiled techniques and strategies for identifying protein coronas adsorbed on diverse types of polymer nanoparticles, showing varied adsorption amount and type based on hydrophobicity.
31. De M., You C.C., Srivastava S., and Rotello V.M. Biomimetic interactions of proteins with functionalized nanoparticles: a thermodynamic study. J Am Chem Soc 129 (2007) 10747-10753
32. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., Lee L.K., Swartz M.A., and Hubbell J.A. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotech 25 (2007) 1159-1164. Very insightful work. The combined effect of size dependent cellular uptake and nanoparticle surface chemistry based complement activation on subsequent dendritic cell maturation is very clearly explored, showing that methoxy-polyethylene glycol coatings avoid C3 activation.
33. Fischer H.C., Liu L., Pang K.S., and Chan W.C.W. Pharmacokinetics of nanoscale quantum dots: in vivo distribution, sequestration, and clearance in the rat. Adv Funct Mater 16 (2006) 1299-1305. The first complete quantitative in vivo pharmacokinetics study on QDs. The authors use ICP-AES to quantify quantum dot distribution showing MPS uptake and no excretion; a useful outline of techniques applicable to tracking QD in vivo.
34. Liu Z., Cai W., He L., Nakayama N., Chen K., Sun X., Chen X., and Dai H. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nano 2 (2007) 47-52
35. Saba T. Physiology and physiopathology of the reticuloendothelial system. Arch Intern Med 126 (1970) 1031-1052
36. Paciotti G.F., Myer L., Weinreich D., Goia D., Pavel N., McLaughlin R.E., and Tamarkin L. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Delivery 11 (2004) 169-183
37. 111In to quantify organ distribution, and TEM to show that functionalized SWCNT are excreted in urine.
38. Khan M.K., Nigavekar S.S., Minc L.D., Kariapper M.S.T., Nair B.M., Lesniak W.G., and Balogh L.P. In vivo biodistribution of dendrimers and dendrimer nanocomposites - implicaitons for cancer imaging and therapy. Tech Canc Res Treat 4 (2005) 603-613
39. Ballou B., Lagerholm B.C., Ernst L.A., Bruchez M.P., and Waggoner A.S. Noninvasive imaging of quantum dots in mice. Bioconj Chem 15 (2004) 79-86
40. Hardonk M.J., Harms G., and Koudstaal J. Zonal heterogeneity of rat hepatocytes in the in vivo uptake of 17 nm colloidal gold granules. Histochemistry 83 (1985) 473-477
41. Renaud G., Hamilton R.L., and Havel R.J. Hepatic metabolism of colloidal gold-low-density lipoprotein complexes in the rat: evidence for bulk excretion of lysosomal contents into bile. Hepatology 9 (1989) 380-392
42. Wang H., Wang J., Deng X., Sun H., Shi Z., Gu Z., Liu Y., and Zhao Y. Biodistribution of carbon single-wall carbon nanotubes in mice. J Nanosci Nanotechnol 4 (2004) 1019-1024
43. Choi H.S., Liu W., Misra P., Tanaka E., Zimmer J.P., Ipe B.I., Bawendi M.G., and Frangioni J.V. Renal clearance of quantum dots. Nat Biotech 25 (2007) 1165-1170. The effect of quantum dot size on urine clearance is explored. In addition to demonstrating a clear size cutoff for urine clearance, the authors show a clear need for a Zwitterionic cysteine coating resistant to protein adsorption, making the quantum dots capable of maintaining the required final diameter of less than 5.5 nm.
44. Kooter I.M., Pennings J.L.A., Opperhuizen A., and Cassee F.R. Gene expression pattern in spontaneously hypertensive rats exposed to urban particulate matter (EHC-93). Inhal Toxicol 17 (2005) 53-65
45. Maysinger D., Behrendt M., Lalancette-Hebert M., and Kriz J. Real-time imaging of astrocyte response to quantum dots: in vivo screening model system for biocompatibility of nanoparticles. Nano Lett 7 (2007) 2513-2520
46. Fifis T., Crimeen-Irwin B., Pietersz G.A., Li J., Motram P.L., McKenzie I.F.C., and Plebanski M. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 173 (2004) 3148-3154. The authors show, with polystyrene nanoparticle vaccines, a cellular distribution dependence on nanoparticle size.
47. Gamvrellis A., Leong D., Hanley J.C., Xiang S.D., Mottram P., and Plebanski M. Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell BioI 82 (2004) 506-516
48. Sayes C.M., Reed K.L., and Warheit D.B. Assessing toxicology of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles. Toxicol Sci 97 (2007) 163-180
49. Sayes C.M., Marchione A.A., Reed K.L., and Warheit D.B. Comparative pulmonary toxicity assessments of C60 water suspensions in rats: few differences in fullerene toxicity in vivo in contrast to in vitro profiles. Nano Lett 7 (2007) 2399-2406. Excellent study comparing common in vitro techniques to the in vivo systems they are meant to emulate; results show that data from in vitro studies could be misleading.
50. Yates J.R.W., Sepp T., Matharu B.K., Khan J.C., Thurlby D.A., Shahid H., Clayton D.G., Hayward C., Morgan J., Wright A.F., et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 357 (2007) 553-561
51. Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ Health Perspect 114 (2006) 165-172. Very good discussion of the recent but limited proper toxicological study of QD. The physicochemical inconsistencies and exposure routes are treated from a mechanistic angle.
52. Gopee N.V., Roberts D.W., Webb P., Cozart C.R., Siitonen P.H., Warbritton A.R., Yu W.V., Colvin V.L., Walker N.J., and Howard P.C. Migration of intradermally injected quantum dots to sentinel organs in mice. Toxicol Sci 98 (2007) 249-257
53. Asuri P., Bale S.S., Karajanagi S.S., and Kane R.S. The protein-nanomaterial interface. Curr Opin Biotech 17 (2006) 562-568
54. James W.D., Hirsch L.R., West J.L., O'Neal P.D., and Payne J.D. Application of INAA to the build-up and clearance of gold nanoshells in clinical studies in mice. J Radioanal Nucl Chem 271 (2007) 455-459